Thank you.
Based on this:
* I like the answers for the betabodies patent, imaging, viral, enrollment trends, KOLs, and BTD.
* I still think the first look-in might give us the required boost.
* Ebola...I don't even know what to think of it anymore except that I'd give it just a little bit time, a couple of weeks maybe; if we are successful we might ride the wave here.
* Betabodies in preclinical, why still, what's the problem, would be my follow-up question, since the other answers are unusually honest.
Market Data 
Markets 
AI
